Table 1 Patient demographics and baseline characteristics (n = 23).

From: High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration

 

Mean

 ± SD

Range

Gender: M/F, n (%)

7 (30.4)/16 (69.6)

  

Age, years

82.3

6.8

66–93

N ranibizumab injections

7.86

5.06

1–19

CRT, µm

418.7

132.6

289–757

BCVA, ETDRS letters

67.8

9.58

39–78

Morphological finding

Proportion, n (%)

  

PVD

17 (73.9)

  

RPE atrophy

9 (39.1)

  

SR hemorrhage

5 (21.7)

  

IS/OS line disruption

20(86.9)

  

ELM disruption

19(82.6)

  
  1. F female, M male, N number, NA not applicable, SD standard deviation, CRT central retinal thickness, BCVA best-corrected visual acuity, ETDRS Early Treatment Diabetic Retinopathy Study, PVD posterior vitreous detachment, RPE retinal pigment epithelium, SR sub-retinal, IS/OS photoreceptor inner/outer segment (IS/OS) junction line, ELM external limiting membrane.
Back to article page